Home  /  Resource Library  /  Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

Retrospective study examined the outcomes of follicular lymphoma patients who received first line treatment with rituximab plus bendamustine.